114 related articles for article (PubMed ID: 8749837)
41. Personality disorder scores improve with effective pharmacotherapy of depression.
Black KJ; Sheline YI
J Affect Disord; 1997 Mar; 43(1):11-8. PubMed ID: 9127826
[TBL] [Abstract][Full Text] [Related]
42. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine.
Faramarzi M; Alipor A; Esmaelzadeh S; Kheirkhah F; Poladi K; Pash H
J Affect Disord; 2008 May; 108(1-2):159-64. PubMed ID: 17936366
[TBL] [Abstract][Full Text] [Related]
43. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley CM; Dornseif BE; Bosomworth JC; Sayler ME; Rampey AH; Heiligenstein JH; Thompson VL; Murphy DJ; Masica DN
BMJ; 1991 Sep; 303(6804):685-92. PubMed ID: 1833012
[TBL] [Abstract][Full Text] [Related]
44. Age may affect response to antidepressants with serotonergic and noradrenergic actions.
Mulder RT; Watkins WG; Joyce PR; Luty SE
J Affect Disord; 2003 Sep; 76(1-3):143-9. PubMed ID: 12943944
[TBL] [Abstract][Full Text] [Related]
45. Fluoxetine-tricyclic combinations.
Zelwer A
Aust N Z J Psychiatry; 1993 Jun; 27(2):350, 352. PubMed ID: 8363551
[No Abstract] [Full Text] [Related]
46. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Uher R; Dernovsek MZ; Mors O; Hauser J; Souery D; Zobel A; Maier W; Henigsberg N; Kalember P; Rietschel M; Placentino A; Mendlewicz J; Aitchison KJ; McGuffin P; Farmer A
J Affect Disord; 2011 Jul; 132(1-2):112-20. PubMed ID: 21411156
[TBL] [Abstract][Full Text] [Related]
47. [A case of allergic cross reaction between tricyclic antidepressants and maprotiline].
Shimizu K; Watanabe M; Kodama Y; Nomura S
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Aug; 18(4):129-32. PubMed ID: 9866828
[TBL] [Abstract][Full Text] [Related]
48. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
[TBL] [Abstract][Full Text] [Related]
49. [A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine].
Lopukhov IG
Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(4):53-7. PubMed ID: 9214192
[TBL] [Abstract][Full Text] [Related]
50. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity.
Pillay SS; Yurgelun-Todd DA; Bonello CM; Lafer B; Fava M; Renshaw PF
Biol Psychiatry; 1997 Jul; 42(2):79-84. PubMed ID: 9209723
[TBL] [Abstract][Full Text] [Related]
51. [Therapy of post-stroke depression with fluoxetine. A pilot project].
Stamenkovic M; Schindler S; Kasper S
Nervenarzt; 1996 Jan; 67(1):62-7. PubMed ID: 8676990
[TBL] [Abstract][Full Text] [Related]
52. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Lancaster SG; Gonzalez JP
Drugs; 1989 Feb; 37(2):123-40. PubMed ID: 2649353
[TBL] [Abstract][Full Text] [Related]
53. Are study dropouts different from completers?
Tedlow JR; Fava M; Uebelacker LA; Alpert JE; Nierenberg AA; Rosenbaum JF
Biol Psychiatry; 1996 Oct; 40(7):668-70. PubMed ID: 8886303
[No Abstract] [Full Text] [Related]
54. Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes.
Tollefson GD; Souetre E; Thomander L; Potvin JH
Int Clin Psychopharmacol; 1993; 8(4):281-93. PubMed ID: 8277149
[TBL] [Abstract][Full Text] [Related]
55. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
[TBL] [Abstract][Full Text] [Related]
56. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.
Delgado PL; Miller HL; Salomon RM; Licinio J; Krystal JH; Moreno FA; Heninger GR; Charney DS
Biol Psychiatry; 1999 Jul; 46(2):212-20. PubMed ID: 10418696
[TBL] [Abstract][Full Text] [Related]
57. Venlafaxine: new preparation. Just another antidepressant.
Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950
[TBL] [Abstract][Full Text] [Related]
58. A multicentre open trial of fluoxetine in depressed out-patients in Belgium.
Brasseur R
Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():107-11. PubMed ID: 2644335
[TBL] [Abstract][Full Text] [Related]
59. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study.
Kowatch RA; Carmody TJ; Emslie GJ; Rintelmann JW; Hughes CW; Rush AJ
J Affect Disord; 1999 Aug; 54(3):269-76. PubMed ID: 10467970
[TBL] [Abstract][Full Text] [Related]
60. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response.
Joyce PR; Mulder RT; Luty SE; McKenzie JM; Sullivan PF; Abbott RM; Stevens IF
Aust N Z J Psychiatry; 2002 Jun; 36(3):376-83. PubMed ID: 12060187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
